Aurobindo Pharma reappoints Mukherjee, reports US FDA inspection

Aurobindo Pharma (BSE: AUROPHARMA) has successfully secured shareholder approval for the reappointment of Mr. Santanu Mukherjee as an Independent Director, not liable to retire by rotation, for a five-year term commencing February 9, 2025. The resolution, put forth via postal ballot and remote e-voting, received an overwhelming majority with 91.02% of votes cast in favor. The voting period concluded on March 18, 2025, and the results were based on a scrutinizer's report dated March 19, 2025.